Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that… Read more
Tanvex BioPharma Inc (6541) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.037x
Based on the latest financial reports, Tanvex BioPharma Inc (6541) has a cash flow conversion efficiency ratio of -0.037x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-221.46 Million) by net assets (NT$6.00 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tanvex BioPharma Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Tanvex BioPharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tanvex BioPharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tanvex BioPharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Probi AB
ST:PROB
|
0.045x |
|
Wireless Power Amplifier Module Inc
KQ:332570
|
0.099x |
|
Benchmark Bankshares Inc
PINK:BMBN
|
0.006x |
|
Grupo Gicsa S.A. de C.V
MX:GICSAB
|
0.024x |
|
Sapura Energy Bhd
KLSE:5218
|
-0.224x |
|
B Communications Ltd
PINK:BCOMF
|
0.050x |
|
Polight ASA
OL:PLT
|
-0.042x |
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
-0.074x |
Annual Cash Flow Conversion Efficiency for Tanvex BioPharma Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Tanvex BioPharma Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$893.31 Million | NT$-1.15 Billion | -1.288x | +26.24% |
| 2023-12-31 | NT$821.11 Million | NT$-1.43 Billion | -1.746x | -82.16% |
| 2022-12-31 | NT$1.39 Billion | NT$-1.33 Billion | -0.959x | -93.15% |
| 2021-12-31 | NT$2.79 Billion | NT$-1.39 Billion | -0.496x | +27.24% |
| 2020-12-31 | NT$2.62 Billion | NT$-1.79 Billion | -0.682x | -8.89% |
| 2019-12-31 | NT$3.03 Billion | NT$-1.90 Billion | -0.626x | -64.42% |
| 2018-12-31 | NT$4.21 Billion | NT$-1.61 Billion | -0.381x | -17.86% |
| 2017-12-31 | NT$3.75 Billion | NT$-1.21 Billion | -0.323x | -38.59% |
| 2016-12-31 | NT$3.57 Billion | NT$-833.43 Million | -0.233x | +50.64% |
| 2015-12-31 | NT$1.45 Billion | NT$-684.20 Million | -0.473x | +35.83% |
| 2014-12-31 | NT$589.64 Million | NT$-434.17 Million | -0.736x | -23.91% |
| 2013-12-31 | NT$403.64 Million | NT$-239.86 Million | -0.594x | -- |